1 / 18

Taking Therapeutic Control of the Immune System ™

Taking Therapeutic Control of the Immune System ™. May, 2005. Investment Opportunity. Demonstrated ability to execute business model and establish strategic partnerships Broad pipeline of proprietary product opportunities focused on treatment of immune-mediated disorders

kachina
Download Presentation

Taking Therapeutic Control of the Immune System ™

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Taking Therapeutic Control of the Immune System™ May, 2005

  2. Investment Opportunity • Demonstrated ability to execute business model and establish strategic partnerships • Broad pipeline of proprietary product opportunities focused on treatment of immune-mediated disorders • Experienced and disciplined leadership with strong operational skills

  3. Corporate Strategy Developing a broad pipeline with a risk-reduced approach: • Combination of partnered and internal programs • Synergistic projects with common focus • Effective use of capital

  4. Proven Ability to Partner

  5. Product Pipeline May 2005 CD200Fc IL-1R antag. CD200 Mab

  6. Product Pipeline in 18 months CD200Fc IL-1R antag. CD200 Mab New Product ‘05 New Product ’06

  7. CD200:CD200R is an important immunoregulatory axis  Macrophage activation CD200R  Immune responses CD200 Altered cytokine profile (Th2 > Th1)

  8. CD200-mediated immune suppression CD200Fc: a soluble CD200 fusion protein agonist • In vivo therapeutic benefit in numerous disease models • Broad patent claims granted or allowed in all major markets • > 50 publications (~30 from TTI) • Next Milestone: Selection of clinical development candidate

  9. CD200-mediated immune enhancement CD200 Mab: a neutralizing anti-CD200 monoclonal antibody • Blocking inhibitory molecules has emerged as a viable strategy in cancer (MDX-010 and CP-675206). • CD200 is over-expressed on several types of cancers • In vivo POP demonstrating enhanced tumour immunity • Next Milestone: Expand POP into additional tumour models

  10. 100 80 60 No Treatment CD200Fc 5ug x 3 40 CD200Fc 5 ug x 10 CD200Fc 10 ug x 6 20 0 10 12 14 16 18 20 22 24 26 28 30 Days post transplantation CD200Fc prolongs the survival of skin grafts % surviving grafts

  11. IL-1 Receptor Antagonist Program • Cytokine blockade: a validated therapeutic approach (Enbrel®, Remicade®, Kineret® etc.) • IL-1 is a powerful pro-inflammatory cytokine involved in a number of inflammatory diseases • TTI is developing a series of proprietary peptide antagonists with high invitro potency and remarkable invivo efficacy • Next milestone: Selection of clinical development candidate and design of Phase I trial

  12. IL-1R peptide blocks IL-1b activityin vivo IL-1b(5mg/kg) Mean Blood Pressure 100% IV 80% Oral 60% 40% 20% 0% TTI-110 Saline Control TTI-110

  13. 2004 Highlights • Partnership with Genentech • In-licensed IL-1R antagonist technology • Closed second tranche of C$13.5 million Series A round • CD200 patents granted with broad claims in US and EU 2005 Milestones • Acquire new program • Select clinical candidate in IL-1R program • Establish additional POP in CD200Mab program • Meet first development milestone in Genentech agreement

  14. Capitalization • $13.5 M Series A financing (2004) • $250 K Seed financing (1998) • $4.8 M Pharma contract research (1996-2001) Major Shareholders • Vengrowth Advanced Life Sciences Fund • Canadian Medical Discoveries Fund • Business Development Bank of Canada

  15. Experienced Leadership • Niclas Stiernholm, Ph.D. Chief Executive Officer (Allelix, YM Biosciences, ) • Bob Uger, Ph.D. Vice President, R&D (Aventis Pasteur) • Jennifer Pendlebury, M.Sc. Director, Regulatory Affairs (Sanofi) • James Parsons, CA Director, Finance & Admin. (Lorus Therapeutics) • Scott Duncan, B.Sc. Director, Patents & Licensing (Allelix)

  16. Calvin Stiller, MD (Chair) Chairman, Canadian Medical Discoveries Fund Brian Underdown, Ph.D. Managing Director, MDS Capital Corp. Niclas Stiernholm, Ph.D. TTI CEO Robert Hall, M.B.A. Director, VC Division, Bus. Dev. Bank of Canada Julia Levy, Ph.D. Founder and Former President & CEO, QLT Inc. Elizabeth Corsi, Pharm D. Former President & CEO Eximias Pharm. Corp. Michael Moore, Ph.D. D.Sc. CEO, PIramed Ltd. Gary Levy, M.D. TTI Founding Scientist Representative Diverse Board of Directors

  17. Investment Opportunity • Broad pipeline of proprietary product opportunities focused on treatment of immune-mediated disorders • Demonstrated ability to execute business model and establish strategic partnerships • Experienced and disciplined leadership with strong operational skills

  18. Contacts Niclas Stiernholm, PhD Chief Executive Officer Tel: 416-595-0627 x222 niclas@trilliumtherapeutics.com 96 Skyway Avenue Toronto, Ontario, M9W 4Y9 CANADA Bob Uger, PhD Vice President, R&D Tel: 416-595-0627 x260 bob@trilliumtherapeutics.com

More Related